C diff spores resist bleach and remain viable on surgical scrubs, fabrics

Original Article ↗ Hacker News Discussion ↗

Researchers report that Clostridioides difficile, a dangerous hospital-acquired bacterium, produces spores that can survive bleach and remain viable on fabrics like surgical scrubs and gowns, raising concerns about current disinfection and laundry protocols. Commenters explore implications for hospital design, infection control incentives, and alternative sterilization methods such as autoclaves, UV-C, gamma irradiation, and improved detergents, while sharing stark personal experiences with C. diff and other severe post-surgical infections. The conversation highlights how spore resilience, overuse of antibiotics and antacids, and imperfect hygiene practices combine to make certain infections hard to eradicate and potentially life‑altering.

Hospital-Acquired Infections & System Incentives

  • Several comments stress hospitals are major sources of serious infections (C. diff, MRSA, Pseudomonas), sometimes after “minor” procedures.
  • Disagreement on US hospitals’ incentives:
    • One view: administration aims only for “good enough” to avoid lawsuits.
    • Counterview: strong incentives exist because insurers/Medicare don’t cover hospital-acquired infections and 30‑day readmission/mortality metrics are tracked.
  • Moral hazard concern (not diagnosing infections) is raised; clinicians respond that missing early infections usually makes costs and outcomes worse, so there’s strong pressure to diagnose.

Infection Control, Scrubs, and Sterilization

  • Core paper point reiterated: C. diff spores can survive bleach and remain viable on fabrics, especially when surfaces are bleached but fabrics contact them too soon.
  • Some note this doesn’t prove hot washing with detergent and agitation is ineffective; detachment plus washing may still work.
  • Suggested measures: autoclaving, hot washes, gamma irradiation, UV‑C, ozone, cold plasma; debate on practicality, cost, and equipment safety.
  • UK/other systems mentioned: no ties/long sleeves, routine MRSA screening, more use of scrubs; some US hospitals still use formal dress.
  • Prions cited as an example of pathogens that can survive standard autoclave cycles, prompting talk of incineration for extreme cases.

C. diff Biology & Disinfectants

  • C. diff spores are known to resist alcohol; handwashing with soap and water is recommended when visibly soiled, sanitizer otherwise.
  • Discussion of how spores can be “resistant” to alcohol or bleach: they don’t grow in pure alcohol but can survive limited exposure; survival depends on contact time and conditions.
  • Some technical discussion of chlorine species (HOCl vs OCl⁻ vs chlorinated cyanurates) and that efficacy depends on concentration and pH.

Personal Experiences & Risk Perception

  • Multiple stories: C. diff after chemo or surgery, long hospitalizations, severe weight loss, months-long antibiotics, and life disruption (e.g., two years of college missed).
  • Other dramatic infection stories include necrotizing fasciitis after a chest tube, septic arthritis from Pseudomonas, post-appendicitis abscesses, and fatal hospital infections.
  • These anecdotes fuel fear of “minor” procedures and hospitals, though several commenters warn against basing decisions solely on anecdotes and emphasize risk–benefit tradeoffs.

Treatment Options & Gut Microbiome

  • Antibiotics for C. diff (metronidazole, vancomycin, fidaxomicin/Dificid) are characterized as imperfect and expensive; success rates around or under ~70% are mentioned.
  • Fecal microbiota transplantation (FMT) is repeatedly described as highly effective for recurrent C. diff; it is usually a “last resort” but some feel it should be used earlier.
  • Cost and access issues: FMT may be covered in some systems but not others; new oral FMT products (e.g., Vowst) are noted as expensive.
  • Long-term antacid/PPI use is suspected by some posters as a C. diff risk factor; others note PPIs are standard of care but acknowledge growing concern over long-term side effects.

Resistance, Evolution, and Pharma Incentives

  • Some worry that stronger disinfectants and longer contact times will select for ever more resistant spore-formers; others note evolutionary trade-offs likely limit “super-resistance.”
  • Pharma discussion:
    • One line of argument: curing chronic infections could be very profitable because it displaces competitors.
    • Another emphasizes real-world incentives and examples where companies prioritized lucrative indications over high-burden but poorer markets (e.g., TB vs shingles vaccines).

Other Side Topics

  • Home canning and Clostridium botulinum spores are discussed as a parallel for spore toughness and the importance of pH/pressure.
  • Ideas floated: more telemedicine to limit hospital exposure; copper/silver surfaces (oligodynamic effect); speculative implications for life on Mars.
  • Overall tone: mixture of technical curiosity, alarm about hospital infections, and debate over how far to push sterilization vs practicality.